Search

everythinglearnresearchcommunity

for

Search:↓

A new mutation in the PLEC gene causes a rare condition with skin blistering, muscle weakness, and hair loss.

A patient with a new PLEC gene mutation showed symptoms of both muscular dystrophy and myasthenia gravis, which improved with steroid treatment.

A patient with a PLEC mutation has epidermolysis bullosa, muscular dystrophy, and myasthenia gravis, which improved with steroid treatment.

Corticosteroids, especially prednisone, improve short-term muscle strength in Duchenne muscular dystrophy but have manageable side effects.

Glucocorticoid corticosteroids improve muscle strength in Duchenne muscular dystrophy but can cause side effects.

Glucocorticoids for progressive muscular dystrophy in children don't improve muscle strength or function but do increase certain side effects.

CRISPR gene editing reduces harmful molecules in cells from Emery–Dreifuss Muscular Dystrophy patients.

LncRNAs play a crucial role in muscle regulation and could help develop treatments for Duchenne muscular dystrophy.

People with Collagen VI-related myopathies may often have hair loss and scalp issues.

The boy's symptoms suggest a possible new medical condition.

DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.

Using CRISPR for gene editing in the body is promising but needs better delivery methods to be more efficient and specific.

Intermediate filaments are crucial for cell differentiation and stem cell function.

Myoblast transplantation shows promise for treating various muscle and heart conditions.

The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.

Organoid technology is advancing and entering commercial use, with applications in disease modeling, drug development, and personalized medicine.

AI and advanced technologies are improving medical diagnostics and treatments.

New technologies show promise in healing wounds, treating cancer, autoimmune diseases, and genetic disorders.

The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

People with myotonic dystrophy type 1 have a higher chance of getting skin tumors, including melanoma.

People with Myotonic Dystrophy type 1 are more likely to have certain skin conditions, but not more likely to get skin cancer.

Women with myotonic dystrophy might get diseases related to male hormones because their body tissues are extra sensitive to these hormones.

Patients with myotonic dystrophy often have skin problems that suggest early aging and vitamin D issues, and the severity of these problems is linked to their genetic condition and vitamin D levels.

Myotonic dystrophy should be considered in patients with hair thinning, and genetic counseling is important.

There is no cure for myotonic dystrophy type 1, so treatment focuses on managing symptoms and complications.

Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.

Effective treatments for spinal and bulbar muscular atrophy are not yet available; more research is needed.

Botulinum toxin-A injections in the scalp can reduce hair loss and promote new hair growth in men with certain types of baldness.

Myotonic dystrophy may be classified as a segmental progeroid disorder.